Sunshine Biopharma's Q2 Loss Deepens as ATM Sales Add $1.7M and Warrant Overhang Expands
SBFM is trading near its 52-week low of $1.1 (5.5% above the low) on light trading volume (0.1× avg).
Summary
Q2 loss narrows slightly but gross margin falls sharply; ATM sales and warrant adjustments add significant dilution risk.
Key Events · Earnings and Guidance · SBFM
-
Q2 Net Loss of $1.56M
Revenue fell 1.6% to $9.26M while gross margin dropped to 26.2% from 36.4%, driving a net loss of $1.56M ($1.15 per share).
-
ATM Sales Raise $1.72M
From July 27 to August 12, 2026, the company sold 1,430,521 shares under its $4M ATM program for $1,722,555 in net proceeds.
-
Series B Warrant Overhang Expands
ATM sales triggered an adjustment to 25,477,133 Series B warrants at $1.2202 per share, versus 3.88M shares outstanding.
-
Director Compensation in Stock
On August 7, 2026, the company issued 58,300 shares to a director for services, adding to dilution.
Analysis · SBFM · Life Sciences
The Q2 2026 10-Q reveals a net loss of $1.56 million on revenue of $9.26 million, with gross margin compressed to 26.2% from 36.4% a year earlier. A $5.1 million public offering in May was followed by sales of 1.43 million shares under the $4 million ATM, generating $1.72 million in net proceeds. Those ATM sales triggered a Series B warrant adjustment to 25.5 million warrants at $1.22, creating a massive overhang relative to the 3.88 million shares outstanding. Management estimates a cash runway of 27 months, but the warrant structure and continued losses suggest further dilution is likely.
At the time of this filing, SBFM was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.10 to $24.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.